New cell therapy tested in patients with Tough-to-Treat blood cancer
NCT ID NCT05470140
Summary
This early-stage study tested a new cell therapy called WU-NK-101 in patients with acute myeloid leukemia (AML) that had returned or stopped responding to other treatments. The main goals were to find a safe dose and see how well the body tolerates the treatment. Researchers also looked for early signs that the therapy might help control the leukemia.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope
Duarte, California, 91010, United States
-
Norton Health Care
Louisville, Kentucky, 40299, United States
-
Peter MacCallum Cancer Center
Melbourne, Australia
-
Providence Portland Medical Center
Portland, Oregon, 97213, United States
-
Royal Perth Hospital
Perth, Australia
-
Royal Prince Alfred Hospital
Sydney, Australia
-
Stanford Healthcare
Palo Alto, California, 94304, United States
-
University of Maryland
Baltimore, Maryland, 21201, United States
-
Washington University
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.